Who owns Gossamer Bio, Inc. (GOSS)? Elite investor 13F holders
2 tracked elite investors reported holding Gossamer Bio, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | GOSSAMER BIO INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Principal | exited | Original filing |
| D.E. Shaw | GOSSAMER BIO INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 6741898.00 USD | 40959285.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | GOSSAMER BIO INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1914281.00 USD | 11629896.000000 | Shares | add | Original filing |
| Tudor Investment | GOSSAMER BIO INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.